- Home
- IPHA
as of 12-11-2025 4:00pm EST
$1.85
$0.00
0.00%
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Chart Type:
Time Range:
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 174.2M | IPO Year: | 2019 |
| Target Price: | $5.00 | AVG Volume (30 days): | 22.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.47 - $3.51 | Next Earning Date: | 09-17-2025 |
| Revenue: | $14,839,695 | Revenue Growth: | -62.60% |
| Revenue Growth (this year): | 22.29% | Revenue Growth (next year): | 43.90% |
AI-Powered IPHA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.00%
75.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Innate Pharma S.A. ADS News
IPHA Breaking Stock News: Dive into IPHA Ticker-Specific Updates for Smart Investing
24/7 Wall St.
Worried Social Security Won’t Be Enough? Here’s a Strategy to Look At
📊
AI Sentiment
Positive
7/10
CNW Group
Comarch Named a Strong Performer in Loyalty Platforms Evaluation by Independent Research Firm
📈
AI Sentiment
Highly Positive
8/10
Mining Technology
Critical minerals at COP30: the hot topic that didn’t get a mention
➖
AI Sentiment
Neutral
5/10
GlobeNewswire
Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb
📊
AI Sentiment
Positive
7/10
PR Newswire
New Research from Girl Scouts of the USA Finds Girls Turn to Screens Out of Boredom and Fear of Missing Out
➖
AI Sentiment
Neutral
5/10
Compare IPHA vs Leading Stocks
See how IPHA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IPHA Innate Pharma S.A. ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.